RedHill Biopharma (RDHL) Non-Current Deffered Revenue (2018 - 2025)
RedHill Biopharma (RDHL) posted quarterly Non-Current Deffered Revenue of $500000.0 for Q4 2025, little changed year-over-year from $500000.0 in Q4 2024, and little changed quarter-over-quarter from $500000.0 in Q2 2025.
RedHill Biopharma (RDHL) Non-Current Deffered Revenue (2018 - 2025) Analysis & Trends
RedHill Biopharma (RDHL) has reported Non-Current Deffered Revenue for 8 consecutive years, with $500000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Deffered Revenue changed 0.0% year-over-year to $500000.0; the TTM figure through Dec 2025 stood at $500000.0 (changed 0.0% YoY), while the FY2025 annual figure was $500000.0, changed 0.0% from the prior year.
- Non-Current Deffered Revenue steadied at $500000.0 in Q4 2025 per RDHL's latest filing, from $500000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $750000.0 in Q1 2021 and bottomed at $500000.0 in Q4 2024.
- Historically, Non-Current Deffered Revenue has averaged $672000.0 across 5 years, with a median of $750000.0 in 2021.
- Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue soared 50.0% — and 2023, when it declined 28.0%.
- RedHill Biopharma's Non-Current Deffered Revenue stood at $750000.0 in 2021, then changed by 0.0% to $750000.0 in 2022, then slipped by 28.0% to $540000.0 in 2023, then declined by 7.41% to $500000.0 in 2024, then changed by 0.0% to $500000.0 in 2025.
- Business Quant data shows RDHL's Non-Current Deffered Revenue at $500000.0 in Q4 2025, $500000.0 in Q2 2025, and $500000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | RedHill Biopharma | 2.05 Bn | 2.05 Bn | - | 500,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Jun 30, 2024 | 540,000.00 |
| Dec 31, 2023 | 540,000.00 |
| Jun 30, 2023 | 750,000.00 |
| Mar 31, 2023 | 750,000.00 |
| Dec 31, 2022 | 750,000.00 |
| Sep 30, 2022 | 750,000.00 |
| Jun 30, 2022 | 750,000.00 |
| Mar 31, 2022 | 750,000.00 |
| Dec 31, 2021 | 750,000.00 |
| Sep 30, 2021 | 750,000.00 |
| Jun 30, 2021 | 750,000.00 |
| Mar 31, 2021 | 750,000.00 |
| Dec 31, 2020 | 750,000.00 |
| Sep 30, 2020 | 500,000.00 |
| Jun 30, 2020 | 500,000.00 |
| Mar 31, 2020 | 500,000.00 |
| Dec 31, 2019 | 500,000.00 |